{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016840","form_type":"8-K","ticker":"TLPH","cik":"0001427925","company_name":"TALPHERA, INC.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.266205+00:00","generated_at":"2026-05-21T08:17:53.648124+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Talphera Q1 2025 net loss narrows to $0.10/share; NEPHRO study reduced to 70 patients","bullets":["Net loss from continuing ops $2.7M vs $4.0M YoY; diluted EPS loss $0.10 vs $0.16.","Cash $5.4M at March 31; adjusted to $9.8M after $4.4M net proceeds from April financing tranche.","FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; primary endpoint powered at 90%.","Three new clinical sites activated in 2025; five more expected by mid-year for total of 13.","2025 cash operating expense guidance $17-19M, including completing registration trial by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016840","json":"https://secwatch.observer/filing/0001437749-25-016840.json","markdown":"https://secwatch.observer/filing/0001437749-25-016840.md","text":"https://secwatch.observer/filing/0001437749-25-016840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1427925/000143774925016840/0001437749-25-016840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1427925/000143774925016840/acrx20250513_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:17:53.648124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}